ERBB2 and cancer: To reduce the number of biopsies and simultaneously increase the patient's quality of life, PET radiolabelled molecules directed against markers which are prognostic and predictive in cancer (i.e., radiolabelled anti-cerb2 antibodies [27] or radiolabelled PSMA inhibitors [28]) have been developed.